KATELYN PARR: Open Payments
NPI 1801513239 · WALDORF, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,759 in 80 payments from 30 companies in 2025. Trend: 2023 $0 · 2024 $1,525 · 2025 $1,759
Food & beverage: $1,759
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $248 |
| Xeris Pharmaceuticals, Inc. | 8 | $160 |
| Novo Nordisk Inc | 10 | $149 |
| SANOFI-AVENTIS U.S. LLC | 4 | $100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $98 |
| Amgen Inc. | 4 | $79 |
| Astellas Pharma US Inc | 3 | $75 |
| Dexcom, Inc. | 2 | $60 |
| RECORDATI_RARE_DISEASES_INC. | 3 | $57 |
| Corcept Therapeutics | 2 | $56 |
Products named: MOUNJARO, JARDIANCE, TZIELD, RECORLEV, Ozempic, Veozah, GVOKE HYPOPEN, TEPEZZA.
Industry payments across MD — which companies pay providers there.
